Menu +

Corcept Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that it has received notice from the NASDAQ Staff that it has regained compliance with NASDAQ’s $1.00 per share bid price requirement. This closes the matter which was raised by the staff in a November 11, 2006 letter in which the Company was notified that it was not in compliance with this listing requirement.

Separately, the Company has been granted a hearing before the NASDAQ Listing Qualifications Panel (the “Panel”) on February 15, 2007 to request continued listing, notwithstanding the fact that the Company does not currently meet the stockholders’ equity requirement for continued listing on The NASDAQ Global Market. The Company intends to present the Panel with its plan to regain, and thereafter sustain, compliance with the $10 million equity requirement. The Company’s stockholders’ equity reported on its Form 10-Q for the period ended September 30, 2006 was $6.98 million. There can, however, be no assurance that the Panel will grant the Company’s request for continued listing.

Statements made in this news release, other than statements of historical fact, are forward-looking statements, including, for example, statements relating to the Company’s prospects regarding continued listing on The NASDAQ Global Market. Forward-looking statements are subject to a number of known and unknown risks and uncertainties that might cause actual results to differ materially from those expressed or implied by such statements, including, without limitation, Corcept’s ability to respond to the Nasdaq compliance concerns to the Nasdaq’s satisfaction and to achieve compliance with Nasdaq Global Market listing standards. These and other risk factors are set forth in the Company's SEC filings, all of which are available from our website (www.corcept.com) or from the SEC's website (www.sec.gov). We disclaim any intention or duty to update any forward-looking statement made in this news release.

CONTACT:
Fred Kurland
Chief Financial Officer
Corcept Therapeutics
650-327-3270
ir@corcept.com
www.corcept.com

built@zoomedia
You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue